SAN JOSE, Calif.,
May 13, 2019 /PRNewswire/
-- Anixa Biosciences, Inc. (NASDAQ: ANIX), a
biotechnology company focused on harnessing the body's immune
system to fight cancer, today announced that its Cchek™ Prostate
Cancer Confirmation (Cchek™ PCC) test successfully passed all
required initial analytical verification studies en route to
commercialization and implementation in the ResearchDx facility.
Having completed this major validation milestone, ResearchDx, a
CLIA-certified laboratory, is now processing the clinical trial
samples received from Anixa's study collaborators and incorporating
the resulting data into the Anixa Artificial Intelligence Training
Dataset. This signals the start of the Database Generation phase of
the ResearchDx clinical validation of Anixa's Cchek™ PCC test.
Dr. Amit Kumar, CEO of
Anixa Biosciences, stated, "We are pleased to announce the
successful completion of the Initial Assay Verification. We are now
actively building and training the required Neural Network. This
milestone demonstrates that we have advanced Cchek™ from a research
environment to a commercial laboratory, an important milestone on
our path to commercialization."
Dr. Mathew Moore, Principal
of ResearchDx, stated, "The Cchek™ PCC test is a novel and highly
sensitive assay designed for the early detection of prostate
cancer. We are excited to continue to collaborate with Anixa on its
innovative Cchek™ platform, and we look forward to the process of
commercialization of the Cchek™ technology."
About Anixa Biosciences,
Inc.
Anixa is a publicly-traded
biotechnology company focused on harnessing the body's immune
system in the fight against cancer. Anixa is developing a
cancer immunotherapy program, which uses chimeric endocrine
receptor t-cell (CER-T) technology, a novel type of CAR-T. Its
Cchek™ liquid biopsy technology is a series of inexpensive
non-invasive blood tests for early detection of solid tumors based
on the body's immune response to the presence of a
malignancy. This technology enables cancer detection in its
earliest stages in efforts to treat patients when the disease is
most curable. Anixa continually examines emerging technologies
in complementary fields for further development and
commercialization. Additional information is available at
www.anixa.com.
About ResearchDx
ResearchDx is a
"full service" Contract Diagnostics Organization dedicated to the
design, development, manufacture and commercialization of
diagnostic testing for the clinical, clinical research and
biopharmaceutical industries. All diagnostic development and
testing services are supported by Pacific Diagnostics (PacificDx),
ResearchDx's CLIA approved, College of American Pathology
accredited and GxP compliant reference laboratory, and Custom
Diagnostics (CustomDx), ResearchDx's ISO13485 accredited
manufacturing facility. Additional information is available
at https://researchdx.com.
Forward-Looking
Statements: Statements that are not
historical fact may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are not statements of
historical facts, but rather reflect Anixa's current expectations
concerning future events and results. We generally use the
words "believes," "expects," "intends," "plans," "anticipates,"
"likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form
8-K. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-completion-of-cchek-analytical-verification-at-clia-laboratory-300848404.html
SOURCE Anixa Biosciences, Inc.